NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球生物標誌物市場(2020-2026)

Biomarker Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 1008105
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
全球生物標誌物市場(2020-2026) Biomarker Market 2020-2026
出版日期: 2021年05月04日內容資訊: 英文
簡介

全球生物標誌物市場按類型(基因組生物標誌物、蛋白質生物標誌物)、應用(藥物發現和開發、診斷、預後、預測等)、疾病(癌症、心臟、腎臟、中心)神經系統疾病)、終端用戶(醫院、診斷中心、調查)、特定區域市場規模預測、份額和趨勢分析報告

在預測期內,全球生物標誌物市場預計將以 14.6% 的複合年增長率增長。生物標誌物是對特定時刻細胞或生物體中發生的事情的客觀測量。生物標誌物充當健康的早期預警系統。生物標誌物可以具有分子、組織學、放射學或生理學特性。生物標誌物在基礎研究和臨床研究以及臨床實踐中的使用已經變得非常普遍,現在幾乎毫無疑問地接受了生物標誌物作為臨床試驗主要終點的存在。

促進全球生物標誌物市場增長的主要因素是慢性病的高患病率、生物標誌物在診斷應用中的採用增加以及政府對癌症研究和臨床試驗的高額資助。包括藥物發現和開發中的使用增加。根據美國國家慢性病預防和健康促進中心 (NCCDPHP) 的一份報告,美國每 10 個成年人中就有 6 個至少患有一種慢性病,而每 10 個成年人中就有 4 個患有一種以上的慢性病。到 2060 年,美國 65 歲及以上人口估計將從目前的 4600 萬增加到 9800 萬。慢性病的高患病率導致對有效生物標誌物的需求,這反過來又進一步推動了市場增長。合同研究組織(CRO)數量的增加和新興市場臨床試驗的低成本預計將進一步推動市場增長。

然而,高投資成本、低迴報率以及樣本收集和存儲等技術問題阻礙了生物標誌物市場的增長。增加政府在研發方面的主動性,引入數字生物標誌物等新技術,以及更多地採用個性化醫療,預計將創造市場友好的機會。

分部展望

全球生物標誌物市場根據類型、用途、疾病和最終用戶進行劃分。根據類型,市場分為基因組和蛋白質生物標誌物。使用細分分為藥物發現和開發、診斷、預後、預測和其他(風險評估)。其中,藥物發現和開發生物標誌物預計將在預測期內以顯著的複合年增長率增長。生物標誌物可以比傳統的臨床終點更快地預測療效。它還可以加速特定疾病領域的產品開發,如癌症和心臟病。疾病段分為癌症、心臟、腎臟、中樞神經系統疾病等(NASH)。最終用戶細分為醫院、診斷中心和研究機構。

癌症疾病部門在全球生物標誌物市場中佔有主要市場份額。

根據疾病,癌症生物標誌物預計將在 2020 年佔據市場主導地位,並在預測期間保持這種主導地位。由於全球癌症患病率不斷上升,近年來對癌症生物標誌物的需求顯著增加,對市場增長產生了積極影響。國際癌症研究機構 (IARC) 估計,2018 年全球有 1700 萬新癌症病例和 950 萬癌症死亡。到 2040 年,僅由於人口增長和老齡化,全球負擔預計將增加到 2750 萬新癌症病例和 1630 萬癌症死亡。根據世界衛生組織 2020 年的癌症數據,癌症是全球主要的死亡原因。因肺癌(180萬)、結腸直腸癌(93.5萬)、肝癌(83萬)、胃癌(76.9萬)、乳腺癌(68.5萬)等各種癌症導致1000萬人死亡。在癌症研究和藥物發現中,生物標誌物具有診斷(支持早期診斷病情)、預後(用於預測病情進展)和預測(用於預測治療後的反應)。它以三種方式使用.預計癌症患病率的增加將增加生物標誌物在研究相關活動中的使用,並進一步推動市場增長。

區域展望

從地域上看,全球生物標誌物市場是北美(美國和加拿大)、歐洲(英國、德國、法國、意大利、西班牙、俄羅斯和其他歐洲)、亞太地區(印度、中國、日本、韓國)。和其他亞太地區)和其他地區(拉丁美洲、中東和非洲 (MEA))。其中,亞太地區是預測期內增長最快的地區。促進區域增長的因素包括中國、日本和印度等國家強大的人口基礎和癌症和心血管疾病等慢性病的高患病率。除此之外,該地區的生物製藥研究中心也有所改善,臨床研究也有所增加。

預計北美將主導生物標誌物市場

從地理位置來看,預計北美將在 2020 年佔據主要市場份額,並在預測期內主導市場。對市場做出貢獻的主要經濟體是美國和加拿大。對市場增長有顯著貢獻的因素包括發達的醫療保健基礎設施、醫療保健研發投資的增加以及高昂的醫療保健成本。越來越多的癌症患者被認為是推動北美市場增長的關鍵驅動因素之一。美國的醫療保健成本比率高於加拿大,因為美國政府正在加大對研發的投資。此外,健康、收入和人口基數等社會經濟因素在美國創造的商機比在加拿大多。

市場參與者展望

生物標誌物市場的主要參與者通過提供種類繁多的產品並擴大其在全球的地理分佈做出了重大貢獻。市場上的主要參與者是,除其他外Abbott Laboratories, Bio-Rad Laboratories Inc, Enzo Biochem Inc., EKF Diagnostics Holdings plc, PerkinElmer Inc, QIAGEN GmbH, Cisbio Bioassays, Johnson & Johnson Services, Inc.。為了在市場中生存,這些市場參與者採用了多種營銷策略,例如併購、研發、產品發佈和地域擴張。例如,2020 年 12 月,Personalis, Inc. 宣佈推出自己的新抗原呈現評分 (NEOPS)。它是一種新的基於抗原的複雜生物標誌物,用於癌症免疫治療反應。 NEOPS 結合 Personalalis、Next Platform 腫瘤基因組和免疫相關分析,創建複雜的生物標誌物,可以更有效地預測免疫治療反應。

本報告涵蓋以下項目

  • 市場價值數據分析和預測。
  • 每個細分市場的年市場收入(以 100 萬美元為單位)。
  • 主要地理區域的國家分析。
  • 在全球氯甲烷市場運營的主要公司。根據數據的可用性,報告中還提供了與新產品發佈和相關新聞相關的信息。
  • 通過確定未來強勁增長的關鍵細分市場來分析業務戰略。
  • 市場進入和市場擴張策略分析。
  • 通過確定誰在市場上的位置來製定競爭策略。

本報告調查了全球生物標誌物市場,概述了市場,分析了市場增長和障礙、市場機會,以及按類型、疾病、疾病、最終用戶和地區劃分的市場規模趨勢和預測。它提供了系統信息,例如競爭情況和主要公司的簡介。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢

第 3 章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 重要的戰略分析
  • Covid-19 對主要參與者的影響

第 4 章市場決定因素

  • 動機
  • 抑制要因
  • 市場機會

第 5 章市場細分

  • 按類型
    • 基因組生物標誌物
    • 蛋白質生物標誌物
  • 按應用程序
    • 藥物發現和開發
    • 診斷
    • 預後
    • 預測
    • 其他(風險診斷)
  • 按疾病分類
    • 癌症
    • 心臟
    • 腎臟
    • 中樞神經系統疾病
    • 其他(Nash)
  • 最終用戶
    • 醫院
    • 診斷中心
    • 調查

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域
    • 拉丁美洲
    • 中東 非洲

第 7 章公司簡介

  • Abbott Laboratories
  • ACS Biomarker B.V.
  • Agilent technologies inc.
  • Abcodia Ltd.
  • Adx Neurosciences
  • Avacta Life Sciences Ltd.
  • Agendia Inc.
  • Astellas Pharma Inc.
  • Angle plc
  • Almac Group
  • Alcediag
  • Banyan Biomarkers Inc.
  • BCAL Diagnostics
  • Bioclinica
  • Biodesix Inc.
  • Bio-Rad Laboratories Inc.
  • BiomarkerBay B. V.
  • BiomarkDiagnostics Inc.
  • BioagilytixLabs LLC
  • BiogazelleNV
  • BiofluidicaInc.
  • Biosims technologies SAS
  • CellomaticsBiosciences Ltd.
  • Celerion
  • Covance Inc.
  • CrossbetaBioscience B.V.
  • Cambridge Biomedical Inc.
  • Charles River Laboratories, Inc.,
  • Danahar Corp.
  • DenovoBiopharma LLC
  • DrumetixLaboratories, LLC
  • Enzo Biochem Inc.
  • ExternauticsSPA
  • EKF Diagnostics Holdings, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Frontage Laboratories, Inc.
  • Future Diagnostics Solutions B.V.
  • GenenewsLtd.
  • GlycotechnicaLtd.
  • HealthspanDiagnostics LLC
  • Hologic inc.
  • Human Longevity, Inc.
  • HvivoServices Ltd.
  • Insight Genetics Inc.
  • Illumina, inc.
  • Icon PLC
  • Johnson &JohnsonServices, Inc.
  • Llckcas-Bioanalytical & Biomarker Services
  • Luminex Corp.
  • LipotypeGmbH
  • Md Biosciences Inc.
  • MdnaLife Sciences Inc.
  • Mdxhealth Group
  • Merck KGaA
  • Meso Scale Diagnostics, LLC
  • Metabolon Inc.
  • MetanomicsHealth GmbH
  • Myriad Genetics Inc.
  • Neogenomics, Inc.
  • NanosomixInc.
  • NanostringTechnologies, Inc.
  • Nordic Bioscience A/S
  • Pfizer Inc.
  • PerkinelmerInc.
  • PamgeneInternational B.V.
  • Pacific Biomarkers Inc.
  • PersonalisInc.
  • Precision Medicine Group, Inc.
  • Precision Biomarker Resources Inc.
  • Qiagen GmbH
  • QuanterixCorp.
  • Q2 Solutions
  • RandoxLaboratories Ltd.
  • Response Biomedical Corp.
  • Siemens Healthcare GmbH
  • SignosisInc.
  • SGS SA
  • SynexaLife Sciences BV
  • SteminaBiomarker Discovery, Inc.
  • Thermo Fisher Scientific Inc.
  • TwanBiotech Co., Ltd.
  • TamirnaGmbH
目錄
Product Code: OMR2023398

Global Biomarker Market Size, Share & Trends Analysis Report by Type (Genomic Biomarker, and Protein Biomarker) By Application (Drug Discovery & Development, Diagnostic, Prognostic, Predictive, and Others ) By Disease (Cancer, Cardiac, Renal, Central Nervous System Disease, and Others) By End-User (Hospitals, Diagnostic Centre, and Research Institute) Forecast 2021-2027

The global market for a biomarker is projected to have a CAGR of 14.6% during the forecast period. A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment. Biomarkers can serve as early warning systems for health. Biomarkers can have molecular, histologic, radiographic, or physiological characteristics. The use of biomarkers in basic and clinical research as well as in clinical practice has become so commonplace that their presence as primary endpoints in clinical trials is now accepted almost without question. The key factors contributing to the growth of the global biomarker market include the high prevalence of chronic diseases, rising adoption of the biomarker for diagnostic applications, high government funding for cancer research and clinical trials, increasing application in drug discovery and development. According to the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) report, 6 in 10 adults in America live with at least one chronic disease, and 4 in 10 adults are with two or more. It is estimated that by 2060, the U.S. population aged 65 years and older will more than double, from 46 million today to 98 million. The high prevalence of chronic disease led to the demand for an effective biomarker which, in turn, further drive the market growth. The increase in the number of Contract Research Organizations (CROs) and the low cost of clinical trials in emerging economies are anticipated to further boost the growth of the market.

However, the high investments cost and low-cost benefit ratio and technical issues such as sample collection and storage are restraining the growth of the biomarker market. The increasing government initiatives for R&D, the introduction of new technologies such as digital biomarker and rising adoption in personalized medicine are expected to create lucrative opportunities for the market.

Segmental Outlook

The global biomarker market is segmented based on type, application, disease, and end-user. On the basis of type, the market is bifurcated into genomic and protein biomarker. The application segment is classified into drug discovery & development, diagnostic, prognostic, predictive and others (risk assessment). Among these, the biomarkers in drug discovery and development are anticipated to grow at significant CAGR during the forecast period. Biomarkers can predict the drug efficacy more quickly than conventional clinical endpoints, also they have the potential to accelerate product development in certain disease areas such as cancer, and cardiac disease. The disease segment is segregated into cancer, cardiac, renal, central nervous system disease and others (NASH). The end-user segment is categorized into hospitals, diagnostic center and research institute.

Global Biomarker Market Share by Disease, 2020 (%)

Source: OMR global

The Cancer disease segment holds the Major Market Share in the global Biomarker Market.

Among disease, the biomarker in cancer dominated the market in 2020, and it is anticipated to maintain its dominance during the forecast period. Due to rise in prevalence of cancer cases across the globe, the demand for cancer biomarker has increased significantly in recent years, that has positively impacted the market growth. According to estimates from the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and ageing of the population. According to the WHO data for cancer 2020, cancer is the main cause of death across the globe. There were 10 million deaths accounted for due to various types of cancer such as lung (1.80 million), colon and rectum (935 000), liver (8,30,000), stomach (769 000), and breast (685 000 deaths). In cancer research and drug discovery, biomarkers are used in three ways such as diagnostic (support to diagnose the condition in early-stage), prognostic (to forecast how aggressive a condition is), and predictive (to predict the response after treatment). The rising prevalence of cancer disease will increase the use of biomarkers in research-related activities which will further expected to drive the market growth.

Regional Outlook

Geographically, the global Biomarker market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is the fastest-growing region during the forecast period. The factors contributing to the regional growth include the strong population base, high prevalence of chronic diseases such as cancer and CVDs in countries such as China, Japan, and India. Apart from this, improving biopharmaceutical research centers and rising clinical research in the region.

Global Biomarker Market Growth, by Region 2021-2027

Source: OMR Global

North America is projected to Dominate the Biomarker Market

Geographically, North America held the major market share in 2020, and it is anticipated to dominate the market during the forecast period. Major economies which contribute to the market are the US and Canada. Factors that are contributing significantly to the market growth include the presence of well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and others. The rising number of cancer patients is considered to be one of the major factors that are driving the growth of the market in the North American region. The healthcare expenditure rate of the US is more than that of Canada, as the US government invests more in R&D. Furthermore, socioeconomic factors such as health, income, population base creates more business opportunity in the US as compared to Canada.

Market Players Outlook

The key players in the biomarker market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Abbott Laboratories, Bio-Rad Laboratories Inc, Enzo Biochem Inc., EKF Diagnostics Holdings plc, PerkinElmer Inc, QIAGEN GmbH, Cisbio Bioassays, Johnson & Johnson Services, Inc., among others. To survive in the market, these market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions so on. For instance, in December 2020, Personalis, Inc. announced the launch of proprietary Neoantigen Presentation Score (NEOPS). It is a neoantigen-based composite biomarker for cancer immunotherapy response. NEOPS combines the tumor genomic and immune-related analytics of the Personalis, Next Platform in order to create a composite biomarker through which immunotherapy response can be predicted more effectively.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global biomarker market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Biomarker Industry
  • Recovery Scenario of Global Biomarker Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Biomarker Market, ByType
    • 5.1.1. Genomic Biomarker
    • 5.1.2. Protein Biomarker
  • 5.2. Global Biomarker Market, ByApplication
    • 5.2.1. Drug Discovery and Development
    • 5.2.2. Diagnostic
    • 5.2.3. Prognostic
    • 5.2.4. Predictive
    • 5.2.5. Others (Risk Assessment)
  • 5.3. Global Biomarker Market, ByDisease
    • 5.3.1. Cancer
    • 5.3.2. Cardiac
    • 5.3.3. Renal
    • 5.3.4. Central Nervous System Disease
    • 5.3.5. Others (Nash)
  • 5.4. Global Biomarker Market, ByEnd User
    • 5.4.1. Hospitals
    • 5.4.2. Diagnostic Centre
    • 5.4.3. Research Institute

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Russia
    • 6.2.7. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East Africa

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. ACS Biomarker B.V.
  • 7.3. Agilent technologies inc.
  • 7.4. Abcodia Ltd.
  • 7.5. Adx Neurosciences
  • 7.6. Avacta Life Sciences Ltd.
  • 7.7. Agendia Inc.
  • 7.8. Astellas Pharma Inc.
  • 7.9. Angle plc
  • 7.10. Almac Group
  • 7.11. Alcediag
  • 7.12. Banyan Biomarkers Inc.
  • 7.13. BCAL Diagnostics
  • 7.14. Bioclinica
  • 7.15. Biodesix Inc.
  • 7.16. Bio-Rad Laboratories Inc.
  • 7.17. BiomarkerBay B. V.
  • 7.18. BiomarkDiagnostics Inc.
  • 7.19. BioagilytixLabs LLC
  • 7.20. BiogazelleNV
  • 7.21. BiofluidicaInc.
  • 7.22. Biosims technologies SAS
  • 7.23. CellomaticsBiosciences Ltd.
  • 7.24. Celerion
  • 7.25. Covance Inc.
  • 7.26. CrossbetaBioscience B.V.
  • 7.27. Cambridge Biomedical Inc.
  • 7.28. Charles River Laboratories, Inc.,
  • 7.29. Danahar Corp.
  • 7.30. DenovoBiopharma LLC
  • 7.31. DrumetixLaboratories, LLC
  • 7.32. Enzo Biochem Inc.
  • 7.33. ExternauticsSPA
  • 7.34. EKF Diagnostics Holdings, Inc.
  • 7.35. F. Hoffmann-La Roche Ltd.
  • 7.36. Frontage Laboratories, Inc.
  • 7.37. Future Diagnostics Solutions B.V.
  • 7.38. GenenewsLtd.
  • 7.39. GlycotechnicaLtd.
  • 7.40. HealthspanDiagnostics LLC
  • 7.41. Hologic inc.
  • 7.42. Human Longevity, Inc.
  • 7.43. HvivoServices Ltd.
  • 7.44. Insight Genetics Inc.
  • 7.45. Illumina, inc.
  • 7.46. Icon PLC
  • 7.47. Johnson &JohnsonServices, Inc.
  • 7.48. Llckcas- Bioanalytical & Biomarker Services
  • 7.49. Luminex Corp.
  • 7.50. LipotypeGmbH
  • 7.51. Md Biosciences Inc.
  • 7.52. MdnaLife Sciences Inc.
  • 7.53. Mdxhealth Group
  • 7.54. Merck KGaA
  • 7.55. Meso Scale Diagnostics, LLC
  • 7.56. Metabolon Inc.
  • 7.57. MetanomicsHealth GmbH
  • 7.58. Myriad Genetics Inc.
  • 7.59. Neogenomics, Inc.
  • 7.60. NanosomixInc.
  • 7.61. NanostringTechnologies, Inc.
  • 7.62. Nordic Bioscience A/S
  • 7.63. Pfizer Inc.
  • 7.64. PerkinelmerInc.
  • 7.65. PamgeneInternational B.V.
  • 7.66. Pacific Biomarkers Inc.
  • 7.67. PersonalisInc.
  • 7.68. Precision Medicine Group, Inc.
  • 7.69. Precision Biomarker Resources Inc.
  • 7.70. Qiagen GmbH
  • 7.71. QuanterixCorp.
  • 7.72. Q2 Solutions
  • 7.73. RandoxLaboratories Ltd.
  • 7.74. Response Biomedical Corp.
  • 7.75. Siemens Healthcare GmbH
  • 7.76. SignosisInc.
  • 7.77. SGS SA
  • 7.78. SynexaLife Sciences BV
  • 7.79. SteminaBiomarker Discovery, Inc.
  • 7.80. Thermo Fisher Scientific Inc.
  • 7.81. TwanBiotech Co., Ltd.
  • 7.82. TamirnaGmbH

LIST OF TABLES

  • 1. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BYTYPE, 2020-2027($ MILLION)
  • 2. GLOBAL GENOMIC BIOMARKERMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL PROTEIN BIOMARKERMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 5. GLOBAL BIOMARKER FOR DRUG DISCOVERY AND DEVELOPMENTMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL BIOMARKER FOR DIAGNOSTICMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 7. GLOBAL BIOMARKER FOR PROGNOSTICMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL BIOMARKER FOR PREDICTIVEMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL BIOMARKER FOR OTHERS (RISK ASSESSMENT)MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE 2020-2027($ MILLION)
  • 11. GLOBAL BIOMARKER IN CANCER DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 12. GLOBAL BIOMARKER IN CARDIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 13. GLOBAL BIOMARKER IN RENAL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL BIOMARKER IN CENTRAL NERVOUS SYSTEM DISEASEMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL BIOMARKER IN OTHERS(NASH) MARKET RESEARCH AND ANALYSIS BYREGION, 2020-2027($ MILLION)
  • 16. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER 2020-2027($ MILLION)
  • 17. GLOBAL BIOMARKER IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 18. GLOBAL BIOMARKER IN DIAGNOSTIC CENTREMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 19. GLOBAL BIOMARKER IN RESEARCH INSTITUTEMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 20. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027($ MILLION)
  • 21. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 23. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BYAPPLICATION,2020-2027($ MILLION)
  • 24. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BYDISEASE 2020-2027($ MILLION)
  • 25. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BYEND-USER 2020-2027($ MILLION)
  • 26. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 27. EUROPEAN BIOMARKER MARKETRESEARCH AND ANALYSIS BYTYPE, 2020-2027($ MILLION)
  • 28. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BYAPPLICATION, 2020-2027($ MILLION)
  • 29. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BYDISEASE, 2020-2027($ MILLION)
  • 30. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BYEND-USER, 2020-2027($ MILLION)
  • 31. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 32. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 33. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 34. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 35. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 36. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 37. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 38. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 39. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 40. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER , 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL BIOMARKER MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL BIOMARKER MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL BIOMARKER MARKET, 2021-2027 (%)
  • 4. GLOBAL BIOMARKER MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL BIOMARKER MARKET SHARE BY APPLICATION 2020 VS 2027 (%)
  • 6. GLOBAL BIOMARKER MARKET SHARE BY DISEASE, 2020 VS 2027 (%)
  • 7. GLOBAL BIOMARKER MARKET SHARE BY END-USER, 2020 VS 2027 (%)
  • 8. GLOBAL BIOMARKER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL GENOMIC BIOMARKERMARKET SHARE BY REGION, 2020-2027 (%)
  • 10. GLOBAL PROTEIN BIOMARKERMARKET SHARE BY REGION, 2020-2027 (%)
  • 11. GLOBAL BIOMARKER FOR DRUG DISCOVERY AND DEVELOPMENTMARKET SHARE BY REGION, 2020-2027 (%)
  • 12. GLOBAL BIOMARKER FOR DIAGNOSTICMARKET SHARE BY REGION, 2020-2027 (%)
  • 13. GLOBAL BIOMARKER FOR PROGNOSTIC MARKET SHARE BY REGION, 2020-2027 (%)
  • 14. GLOBAL BIOMARKER FOR PREDICTIVE MARKET SHARE BY REGION, 2020-2027 (%)
  • 15. GLOBAL BIOMARKER FOR OTHERS (RISK ASSESSMENT) MARKET SHARE BY REGION, 2020-2027 (%)
  • 16. GLOBAL BIOMARKER IN CANCER DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
  • 17. GLOBAL BIOMARKER IN CARDIAC DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
  • 18. GLOBAL BIOMARKER IN RENAL DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
  • 19. GLOBAL BIOMARKER IN CENTRAL NERVOUS SYSTEM DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
  • 20. GLOBAL BIOMARKER IN OTHERS(NASH) DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
  • 21. GLOBAL BIOMARKER IN HOSPITALS MARKET SHARE BY REGION, 2020-2027 (%)
  • 22. GLOBAL BIOMARKER IN DIAGNOSTIC CENTRE MARKET SHARE BY REGION, 2020-2027 (%)
  • 23. GLOBAL BIOMARKER IN RESEARCH INSTITUTE MARKET SHARE BY REGION, 2020-2027 (%)
  • 24. US BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. CANADA BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. UK BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. FRANCE BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. GERMANY BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. ITALY BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. SPAIN BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. REST OF EUROPE BIOMARKER MARKET SIZE, 2020-2027($ MILLION)
  • 32. INDIA BIOMARKER MARKET SIZE, 2020-2027($ MILLION)
  • 33. CHINA BIOMARKER MARKET SIZE, 2020-2027($ MILLION)
  • 34. JAPAN BIOMARKER MARKET SIZE, 2020-2027($ MILLION)
  • 35. SOUTH KOREA BIOMARKER MARKET SIZE, 2020-2027($ MILLION)
  • 36. ASEAN BIOMARKER MARKET SIZE, 2020-2027($ MILLION)
  • 37. REST OF ASIA-PACIFIC BIOMARKER MARKET SIZE, 2020-2027($ MILLION)

38. REST OF THE WORLD BIOMARKER MARKET SIZE, 2021-2027($ MILLION